Market Closed -
Other stock markets
|
After market 04:00:02 pm | |||
229.9 EUR | -2.75% | 229.1 | -0.35% |
Jul. 15 | Alnylam Pharmaceuticals Insider Sold Shares Worth $1,851,273, According to a Recent SEC Filing | MT |
Jul. 03 | Jerome Powell did it again |
Evolution of the average Target Price on Alnylam Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Alnylam Pharmaceuticals, Inc.
HC Wainwright | |
Chardan Research | |
Goldman Sachs | |
Wolfe Research | |
Morgan Stanley | |
JPMorgan Chase | |
RBC Capital Markets | |
Wells Fargo Securities | |
UBS | |
Oppenheimer | |
Bernstein | |
Evercore ISI | |
TD Cowen | |
BMO Capital | |
Citigroup | |
Needham & Co. | |
Raymond James | |
Canaccord Genuity | |
EF Hutton | |
SVB Securities LLC | |
Piper Sandler | |
Berenberg Bank | |
Jefferies & Co. | |
Cantor Fitzgerald | |
Guggenheim | |
William Blair & Co. | |
SVB Leerink | |
Stifel Nicolaus | |
Chardan | |
Barclays | |
Cowen |
EPS Revisions
- Stock Market
- Equities
- ALNY Stock
- DUL Stock
- Consensus Alnylam Pharmaceuticals, Inc.